Published by Josh White on 31st January 2025
(Sharecast News) - Faron Pharmaceuticals announced on Friday that it has identified the final patient for its BEXMAB phase two dose optimisation study in refractory or relapsed myelodysplastic syndrome (r/r MDS) and its phase one and two study in frontline high-risk (HR) MDS.
URL: http://www.digitallook.com/dl/news/story/34851325/...